RAPT Therapeutics and Jemincare Pharmaceutical Sign an Exclusive License Agreement to Develop JYB1904 (RPT904)
Shots:
- Agreement grants global (excl. mainland China, Hong Kong, Macau & Taiwan) development & commercialization rights of JYB1904 to RAPT in exchange for $35M upfront, up to $672.5M regulatory & commercial milestones plus high single-digit to low-double digit royalties
- RAPT will initiate a P-IIb study of JYB1904 for food allergy in H2’25. Jemincare is assessing it in 2 P-II trials across China for asthma (vs omalizumab; data expected in H2’25) & CSU (data expected H1’26)
- In addition, Jemincare’s completed P-I study of JYB1904 (5 dose levels) vs omalizumab (1 dose level) & PBO in 56 healthy subjects & showed dose-proportional PK, JYB1904's longer half-life, deeper & sustained free IgE reduction & higher total IgE accumulation
Ref: RAPT Therapeutics & Jemincare | Image: RAPT Therapeutics & Jemincare
Related News:- Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
